// App-Quantinova.ai

P3-03-01 : Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer

Researchers

Presenter

  • Neil Vasan

Principal Investigators

  • Jared L Johnson

  • Hong Shao

  • Timothy Wilson

  • Frauke Schimmoller

  • Hardik Shah

  • Alesia Antoine

  • Erik Ladewig

  • Alexander Gorelick

  • Ting-Yu Lin

  • Eneda Toska

  • Guotai Xu

  • Abiha Kazmi

  • Matthew T Chang

  • Barry S. Taylor

  • Maura N. Dickler

  • Komal Jhaveri

  • Sarat Chandarlapaty

  • Raul Rabadan

  • Ed Reznik

  • Melissa L Smith

  • Robert Sebra

  • Lori Friedman

  • Lewis C Cantley

  • Maurizio Scaltriti

  • Jos Baselga

Medical Centers

  • MSKCC, New York, NY

  • Weill Cornell Medical College, New York, NY

  • Roche/Genentech, South San Francisco, CA

  • Mount Sinai School of Medicine, New York, NY

  • Eli Lilly and Company, Indianapolis, IN

  • Columbia University, New York, NY

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Alpelisib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved